Cognition and MRI Markers in MS Patients With Aubagio® Treatment
NCT: NCT03768648 · COMPLETED
Brief Summary
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease which contributes largely to disability. Cognitive assessment using classical neuropsychological tests are poorly correlated with patient's complaints and daily functioning. Ecological evaluations, recent and innovative way to assess cognitive functions with the true impact of cognitive impairment in everyday daily life of patients. One goal of an ecological test could be to identify MS patients in whom cognitive impairment has a strong interaction with daily life. Different type of ecological evaluation have been recently proposed in MS, including assessment cognitive tasks in a virtual reality environment using the Urban DailyCog® software developed in our laboratory (Hamel et al, 2015). Virtual reality environment assessments are promising in detecting cognitive impairment while providing friendly assessments for patients and simulating daily activities. . Cognitive dysfunction is correlated with white matter diffuse injury in relapsing-remitting MS (RRMS) patients and brain atrophy However, the relationships between structural brain damage and brain connectivity with cognitive functioning assessed by ecological evaluation are also unknown. The use of new techniques for morphological and functional MRI can study the contribution of diffuse white matter (WM) alteration and diffuse gray matter (GM) alterations in cognitive impairment and on their evolution. The objectives are to evaluate the ecological assessment (Urban DailyCog® and actual reality) to detect cognitive impairment in everyday daily life of patients and their changes and to investigate structural WM and GM damages and the dynamic of functional connectivity for explaining and predicting cognitive disability during two years in RRMS patients treated by the same treatment Aubagio®.
Frequently Asked Questions
What is Cognition and MRI Markers in MS Patients With Aubagio® Treatment?
Cognition and MRI Markers in MS Patients With Aubagio® Treatment is a clinical trial registered under NCT03768648. Current status: COMPLETED.
What is the status of NCT03768648?
The current status of NCT03768648 (Cognition and MRI Markers in MS Patients With Aubagio® Treatment) is: COMPLETED.
When did Cognition and MRI Markers in MS Patients With Aubagio® Treatment start?
Cognition and MRI Markers in MS Patients With Aubagio® Treatment started on 2019-05-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.